SEC Tracker
Get the app

Nu-Med Plus NUMD

Nu-Med Plus Q1 FY23: net loss $28K; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Nu-Med Plus reported for Q1 FY23, the quarter ended Mar 31, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$28KAgainst −$57K in Q1 FY2210-Q income statement, on EDGAR
  2. Diluted EPS$0.00Against $0.00 in Q1 FY2210-Q income statement, on EDGAR
  3. Cash and cash equivalents$53K+1990% from $3K in Q1 FY2210-Q balance sheet, on EDGAR
  4. Cash from operations−$20KAgainst −$12K in Q1 FY2210-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Nu-Med Plus files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. STRATA Skin Sciences SSKN public float $4M, Jun 30, 2025
  2. ENDRA Life Sciences NDRA public float $3M, Jun 30, 2025
  3. Catheter Precision VJET public float $4M, Jun 30, 2025
  4. Global Innovative Platforms GIPL public float $3M, Sep 30, 2025
  5. Interpace Biosciences IDXG public float $3M, Jun 30, 2025